Does Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Have A Volatile Share Price?

Anyone researching Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. First, we have company specific volatility, which is the price gyrations of an individual stock. Holding at least 8 stocks can reduce this kind of risk across a portfolio. The second sort is caused by the natural volatility of markets, overall. For example, certain macroeconomic events will impact (virtually) all stocks on the market.

Some stocks see their prices move in concert with the market. Others tend towards stronger, gentler or unrelated price movements. Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). While we should keep in mind that Warren Buffett has cautioned that ‘Volatility is far from synonymous with risk’, beta is still a useful factor to consider. To make good use of it you must first know that the beta of the overall market is one. A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

See our latest analysis for Tonix Pharmaceuticals Holding

What does TNXP’s beta value mean to investors?

Looking at the last five years, Tonix Pharmaceuticals Holding has a beta of 1.85. The fact that this is well above 1 indicates that its share price movements have shown sensitivity to overall market volatility. If the past is any guide, we would expect that Tonix Pharmaceuticals Holding shares will rise quicker than the markets in times of optimism, but fall faster in times of pessimism. Share price volatility is well worth considering, but most long term investors consider the history of revenue and earnings growth to be more important. Take a look at how Tonix Pharmaceuticals Holding fares in that regard, below.

NasdaqGM:TNXP Income Statement, March 11th 2019
NasdaqGM:TNXP Income Statement, March 11th 2019

Could TNXP’s size cause it to be more volatile?

With a market capitalisation of US$6.7m, Tonix Pharmaceuticals Holding is a very small company by global standards. It is quite likely to be unknown to most investors. Relatively few investors can influence the price of a smaller company, compared to a large company. This could explain the high beta value, in this case.

What this means for you:

Beta only tells us that the Tonix Pharmaceuticals Holding share price is sensitive to broader market movements. This could indicate that it is a high growth company, or is heavily influenced by sentiment because it is speculative. Alternatively, it could have operating leverage in its business model. Ultimately, beta is an interesting metric, but there’s plenty more to learn. In order to fully understand whether TNXP is a good investment for you, we also need to consider important company-specific fundamentals such as Tonix Pharmaceuticals Holding’s financial health and performance track record. I highly recommend you dive deeper by considering the following:

  1. Future Outlook: What are well-informed industry analysts predicting for TNXP’s future growth? Take a look at our free research report of analyst consensus for TNXP’s outlook.
  2. Past Track Record: Has TNXP been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of TNXP’s historicals for more clarity.
  3. Other Interesting Stocks: It’s worth checking to see how TNXP measures up against other companies on valuation. You could start with this free list of prospective options.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.